Immunogenicity of biotherapy used in psoriasis: the science behind the scenes.

  title={Immunogenicity of biotherapy used in psoriasis: the science behind the scenes.},
  author={Denis Jullien and Joerg Christoph Prinz and Frank O. Nestle},
  journal={The Journal of investigative dermatology},
  volume={135 1},
A potential limitation in the use of biologic drugs used to treat psoriasis is the development of anti-drug antibodies (ADAs). Many factors contribute to this unwanted immune response, from the product itself, to its mode of administration, the underlying disease, and patient characteristics. ADAs may decrease the efficacy of biologic drugs by neutralizing them or modifying their clearance and may account for hypersensitivity reactions. This article reviews the scientific basis of… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 7 times. VIEW TWEETS

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 18 extracted citations

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

Journal of immunology research • 2016
View 4 Excerpts
Highly Influenced

Clinical Cases in Psoriasis

Clinical Cases in Dermatology • 2017
View 1 Excerpt

Etanercept, Adalimumab und Ustekinumab bei Psoriasis: Analyse von 209 Behandlungsreihen in Österreich.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG • 2017

Similar Papers

Loading similar papers…